|By PR Newswire||
|February 12, 2014 07:34 AM EST||
NEW YORK, Feb. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape
GBI Research, has released the pharma report, "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape". The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales.
However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance being achieved in close to 100% of patients and a much improved adverse event profile compared to previous standards of therapy. In patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be administered with pegylated interferon. A number of products in the late-stage pipeline, which promise to be even more efficacious and safe are anticipated to enter the market over the forecast period, including several interferon-free therapies for genotype 1-infected patients. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion.
- A brief introduction to hepatitis C, including the disease's pathogenesis, risk factors and diagnosis, and detailed analyses of disease epidemiology and treatment algorithms.
- In-depth analysis of the major antiviral drugs used in the treatment of hepatitis C, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map that compares marketed drugs in terms of safety and efficacy.
- A comprehensive review of the pipeline for hepatitis C therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed by phase distribution, molecule type and molecular target.
- In-depth clinical trial enrolment, trial duration and program failure rate analyses for each molecule type and mechanism of action. Additionally, clinical trial endpoints and certain selection criteria are analyzed in great depth. This section also includes an additional heat map regarding pipeline products, and a direct cross-analysis against currently marketed products.
- Multi-scenario forecast data of the market to 2019, which takes into account the effects of the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets: US, Canada, Japan, Germany, UK, France, Italy and Spain.
- Discussion of the drivers and barriers for market growth.
- Analysis of licensing and co-development deals occurring in the hepatitis C market.
Reasons to buy
- Understand the different types of hepatitis C therapies and how treatment varies by genotype.
- Understand the treatment algorithms and guidelines related to hepatitis C, how they are anticipated to change during the forecast period and where opportunities and unmet needs lie.
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are most prominent.
- Observe trends in clinical trial duration and size as clinical phase and molecule type varies. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for hepatitis C therapeutics.
- Observe the shift in clinical trial endpoints with each clinical Phase, and use this data to potentially influence any future developmental programs. Additionally, understand the trends in enrolment by patient genotype.
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules and the points of opportunity which remain to be capitalized upon.
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Signs and Symptoms 10
2.2 Etiology and Risk Factors 11
2.3 Pathophysiology 11
2.4 Epidemiology 12
2.4.1 US and Canada 12
2.4.2 Europe 12
2.4.3 Japan 13
2.4.4 Regional Prevalence of Hepatitis C Genotypes 13
2.5 Prognosis 14
2.6 Diagnosis and Screening 16
2.7 Treatment 16
2.8 Treatment Algorithms 17
3 Marketed Products 21
3.1 Ribavirin 21
3.2 Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) – Hoffmann La Roche and Merck & Co 22
3.2.1 Pegasys – Hoffmann La Roche 24
3.2.2 PegIntron – Merck & Co 24
3.3 Incivek (telaprevir) – Vertex Pharmaceuticals and Janssen-Cilag 25
3.4 Victrelis (boceprevir) – Merck & Co 26
3.5 Olysio (simeprevir) – Johnson and Johnson 27
3.6 Sovaldi (sofosbuvir) – Gilead Sciences 28
3.7 Heat Map for Marketed Products 29
4 Developmental Pipeline 31
4.1 Overall Pipeline 31
4.2 Mechanisms of Action 33
4.3 Clinical Trials 35
4.3.1 Clinical Trial Failure Rates 36
4.3.2 Clinical Trial Enrollment 37
4.3.3 Clinical Trial Duration 39
4.3.4 Clinical Trial Design 41
4.4 Promising Pipeline Drugs 44
4.4.1 Sovaldi plus Ledipasvir – Gilead Sciences 44
4.4.2 Daclatasvir – Bristol-Myers Squibb 46
4.4.3 Faldaprevir – Boehringer-Ingelheim 49
4.4.4 Peginterferon lambda 1a – Bristol-Myers Squibb 50
4.4.5 ABT-450 – AbbVie and Enanta 52
4.4.6 Vaniprevir – Merck & Co 54
4.5 Heat Map and Competitor Matrix for Pipeline Products 55
4.6 Conclusion 59
5 Market Forecast to 2019 61
5.1 Global Market 62
5.1.1 Treatment Usage Patterns 62
5.1.2 Market Size 63
5.2 US 65
5.2.1 Treatment Usage Patterns 65
5.2.2 Market Size 66
5.3 Canada 67
5.3.1 Treatment Usage Patterns 67
5.3.2 Market Size 68
5.4 Top Five European Markets 69
5.4.1 Treatment Usage Patterns 69
5.4.2 Annual Cost of Therapy 72
5.4.3 Market Size 74
5.5 Japan 76
5.5.1 Treatment Usage Patterns 76
5.5.2 Market Size 77
6 Drivers and Barriers 78
6.1 Drivers 78
6.1.1 Approval of Sovaldi and Olysio in 2013 78
6.1.2 Large and Exceptionally Promising Late-Stage Pipeline 78
6.1.3 Favorable Pricing Structure in the US 78
6.1.4 Weak Exposure to Generics and Biosimilars during the Forecast Period 79
6.1.5 Increasing Volume of Treated Patients 79
6.1.6 Rapid Incorporation of Novel Products into Treatment Guidelines 79
6.2 Barriers 80
6.2.1 Low Rates of Diagnosis and Treatment in Certain Markets 80
6.2.2 Unfavorable Pricing Structures in the EU and Japan 80
6.2.3 Rapidly Increasing Competition in the Market 80
7 Licensing and Co-development deals 82
7.1 Licensing Deals 82
7.1.1 Vertex Pharma Enters into Licensing Agreement with Alios BioPharma for ALS-2200 and ALS-2158 85
7.1.2 Bristol-Myers Squibb Company Enters into Licensing Agreement with ZymoGenetics 85
7.1.3 Human Genome Sciences Enters Into Licensing Agreement With Novartis 85
7.1.4 Roche Signs Licensing Agreement With InterMune 85
7.1.5 Idenix Enters Into A Licensing Agreement With Novartis Pharma 86
7.1.6 Enanta Pharma Enters into Licensing Agreement with Novartis for Hepatitis C Program 86
7.1.7 Medivir Enters into Licensing Agreement with Tibotec 86
7.1.8 Metabasis Therapeutics Enters Into Collaboration And Licensing Agreement With Roche 86
7.1.9 Schering-Plough And PTC Therapeutics Enter Into A Collaboration And Licensing Agreement 87
7.1.10 Presidio Pharma Enters into Licensing Agreement with XTL BioPharma 87
7.2 Co-development Deals 88
7.2.1 Vertex Pharma Enters into Co-Development Agreement with Janssen Pharmaceutica 89
7.2.2 Abbott Labs Enters into Agreement with Enanta Pharma 89
7.2.3 Genelabs Enters into Collaboration with Novartis 89
7.2.4 Regulus Therapeutics Enters into an Agreement with GlaxoSmithKline 90
7.2.5 Tacere Therapeutics Enters into Agreement with Pfizer 90
7.2.6 Biota Holdings Enters into an Agreement with Boehringer Ingelheim 90
8 Appendix 91
8.1 Sources 91
8.2 Sources for Heat Maps 98
8.3 All Pipeline Products, by Stage of Development 99
8.3.1 Discovery 99
8.3.2 Preclinical and IND/CTA-filed 102
8.3.3 Phase I 106
8.3.4 Phase II 107
8.3.5 Phase III and Pre-registration 110
8.3.6 Undisclosed 111
8.4 Tabular Forecast Data 112
8.4.1 Global 112
8.4.2 US 113
8.4.3 Canada 113
8.4.4 UK 113
8.4.5 France 114
8.4.6 Germany 114
8.4.7 Italy 114
8.4.8 Spain 115
8.4.9 Japan 115
8.5 Market Definition 115
8.6 Abbreviations 115
8.7 Methodology 116
8.7.1 Coverage 116
8.7.2 Secondary Research 117
8.7.3 Primary Research 117
8.7.4 Therapeutic Landscape 117
8.7.5 Epidemiology-Based Forecasting 118
8.7.6 Market Size by Geography 119
8.7.7 Geographical Landscape 120
8.7.8 Pipeline Analysis 120
8.8 Contact Us 120
8.9 Disclaimer 120
List of Tables
Table 1: Hepatitis C, Top Five European Countries, Disease Prevalence (%), 2011 13
Table 2: Hepatitis C, Top Five European Markets, Most Common Risk Factors for Infection (%), 2011 13
Table 3: Hepatitis C, Global, Estimated Distribution of Hepatitis C Genotypes (%), 2013 14
Table 4: Market for Hepatitis C, Sources for Heat Maps 98
Table 5: Hepatitis C Therapeutics, Global, All Pipeline Products (Discovery), 2013 99
Table 6: Hepatitis C Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013 102
Table 7: Hepatitis C, Global, All Pipeline Products (Phase I), 2013 106
Table 8: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase II), 2013 107
Table 9: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase III), 2013 110
Table 10: Hepatitis C Therapeutics, Global, All Pipeline Products (Undisclosed), 2013 111
Table 11: Market for Hepatitis C, Global, Forecast Data, 2012–2019 112
Table 12: Market for Hepatitis C, US, Forecast Data, 2012–2019 113
Table 13: Market for Hepatitis C, Canada, Forecast Data, 2012–2019 113
Table 14: Market for Hepatitis C, UK, Forecast Data, 2012–2019 113
Table 15: Market for Hepatitis C, France, Forecast Data, 2012–2019 114
Table 16: Market for Hepatitis C, Germany, Forecast Data, 2012–2019 114
Table 17: Market for Hepatitis C, Italy, Forecast Data, 2012–2019 114
Table 18: Market for Hepatitis C, Spain, Forecast Data, 2012–2019 115
Table 19: Market for Hepatitis C, Japan, Forecast Data, 2012–2019 115
List of Figures
Figure 1: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Incivek), 2013 18
Figure 2: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Victrelis), 2013 19
Figure 3: Market for Hepatitis C, Global, Treatment Algorithm (Genotypes 2 to 7), 2013 20
Figure 4: Market for Hepatitis C, Global, Sales of Pegasys and PegIntron ($m), 2002–2012 22
Figure 5: Market for Hepatitis C, Global, Heat Map for Marketed Products, 2013 30
Figure 6: Market for Hepatitis C, Global, Developmental Pipeline, 2013 32
Figure 7: Market for Hepatitis C, Global, Pipeline by Mechanism of Action and Molecule Type, 2013 33
Figure 8: Market for Hepatitis C, Global, Clinical Trial Failure Rate by Molecule Type, 2006–2013 36
Figure 9: Market for Hepatitis C, Global, Clinical Trial Failure Rates by Mechanism of Action, 2006–2013 37
Figure 10: Market for Hepatitis C, Global, Clinical Trial Enrollment by Molecule Type, 2006–2013 38
Figure 11: Market for Hepatitis C, Global, Clinical Trial Enrollment by Mechanism of Action, 2006–2013 39
Figure 12: Market for Hepatitis C, Clinical Trial Duration by Molecule Type, 2006–2013 40
Figure 13: Market for Hepatitis C, Global, Clinical Trial Duration by Mechanism of Action, 2006–2013 41
Figure 14: Market for Hepatitis C, Global, Frequency of Clinical Trial Primary Endpoints Per Clinical Trial, 2006–2013 42
Figure 15: Market for Hepatitis C, Global, Frequency of Clinical Trial Endpoints Primary within Clinical Development Programs, 2006–2013 43
Figure 16: Market for Hepatitis C, Global, Usage of HCV Genotypes as Clinical Trial Inclusion Criteria, 2006–2013 44
Figure 17: Market for Hepatitis C, Global, Sales Forecast for Sovaldi plus ledipasvir ($m), 2015–2019 45
Figure 18: Market for Hepatitis C, Global, Sales Forecast for daclatasvir (monotherapy) ($m), 2015–2019 47
Figure 19: Market for Hepatitis C, Global, Sales Forecast for daclatasvir plus asunaprevir plus BMS-791325 ($m), 2015–2019 48
Figure 20: Market for Hepatitis C, Global, Sales Forecast for faldaprevir ($m), 2015–2019 50
Figure 21: Market for Hepatitis C, Global, Sales Forecast for peginterferon lambda 1a ($m), 2015–2019 51
Figure 22: Market for Hepatitis C, Global, Sales Forecast for ABT-450 ($m), 2015–2019 52
Figure 23: Market for Hepatitis C, Global, Sales Forecast for ABT-450 plus ABT-333 plus ABT-267 ($m), 2015–2019 54
Figure 24: Market for Hepatitis C, Global, Sales Forecast for vaniprevir, 2015–2019 55
Figure 25: Market for Hepatitis C, Global, Heat Map for Pipeline Products, 2013 57
Figure 26: Market for Hepatitis C, Global, Competitor Matrix, 2013 58
Figure 27: Market for Hepatitis C, Global, Market Growth and Size, 2012–2019 61
Figure 28: Market for Hepatitis C, Global, Treatment Patterns, 2012–2019 63
Figure 29: Market for Hepatitis C, Global, Market Size ($bn), 2012–2019 64
Figure 30: Market for Hepatitis C, US, Treatment Usage Patterns, 2012–2019 65
Figure 31: Market for Hepatitis C, US, Market Size ($bn), 2012–2019 66
Figure 32: Market for Hepatitis C, Canada, Treatment Usage Patterns, 2012–2019 67
Figure 33: Market for Hepatitis C, Canada, Market Size ($m), 2012–2019 68
Figure 34: Market for Hepatitis C, Top Five European Markets, Treatment Patterns, 2012–2019 69
Figure 35: Market for Hepatitis C, Top Five European Markets, Annual Cost of Therapy ($), 2012–2019 72
Figure 36: Market for Hepatitis C, Top Five European Markets, Market Size ($m), 2012–2019 74
Figure 37: Market for Hepatitis C, Japan, Treatment Usage Patterns, 2012–2019 76
Figure 38: Market for Hepatitis C, Japan, Market Size ($m), 2012–2019 77
Figure 39: Market for Hepatitis C, Global, Network of Licensing Deals, 2006–2013 82
Figure 40: Market for Hepatitis C, Global, Licensing Deals by Year, 2006–2013 83
Figure 41: Market for Hepatitis C, Global, Licensing Deals, 2006–2013 84
Figure 42: Market for Hepatitis C, Global, Network of Co-Development Deals, 2006–2013 88
Figure 43: Market for Hepatitis C, Global, Co-Development Deals by Year, 2006–2013 89
Figure 44: GBI Research Market Forecasting Model 119
To order this report: Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape
Contact Clare: [email protected]
Intl: +1 339-368-6001
I recently attended and was a speaker at the 4th International Internet of @ThingsExpo at the Santa Clara Convention Center. I also had the opportunity to attend this event last year and I wrote a blog from that show talking about how the “Enterprise Impact of IoT” was a key theme of last year’s show. I was curious to see if the same theme would still resonate 365 days later and what, if any, changes I would see in the content presented.
Dec. 1, 2015 03:00 AM EST Reads: 455
The revocation of Safe Harbor has radically affected data sovereignty strategy in the cloud. In his session at 17th Cloud Expo, Jeff Miller, Product Management at Cavirin Systems, discussed how to assess these changes across your own cloud strategy, and how you can mitigate risks previously covered under the agreement.
Dec. 1, 2015 03:00 AM EST
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Dec. 1, 2015 03:00 AM EST Reads: 456
Most of the IoT Gateway scenarios involve collecting data from machines/processing and pushing data upstream to cloud for further analytics. The gateway hardware varies from Raspberry Pi to Industrial PCs. The document states the process of allowing deploying polyglot data pipelining software with the clear notion of supporting immutability. In his session at @ThingsExpo, Shashank Jain, a development architect for SAP Labs, discussed the objective, which is to automate the IoT deployment proces...
Dec. 1, 2015 01:15 AM EST Reads: 109
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...
Dec. 1, 2015 01:00 AM EST Reads: 433
In his General Session at DevOps Summit, Asaf Yigal, Co-Founder & VP of Product at Logz.io, explored the value of Kibana 4 for log analysis and provided a hands-on tutorial on how to set up Kibana 4 and get the most out of Apache log files. He examined three use cases: IT operations, business intelligence, and security and compliance. Asaf Yigal is co-founder and VP of Product at log analytics software company Logz.io. In the past, he was co-founder of social-trading platform Currensee, which...
Nov. 30, 2015 10:00 PM EST Reads: 282
Countless business models have spawned from the IaaS industry – resell Web hosting, blogs, public cloud, and on and on. With the overwhelming amount of tools available to us, it's sometimes easy to overlook that many of them are just new skins of resources we've had for a long time. In his general session at 17th Cloud Expo, Harold Hannon, Sr. Software Architect at SoftLayer, an IBM Company, broke down what we have to work with, discussed the benefits and pitfalls and how we can best use them ...
Nov. 30, 2015 03:45 PM EST Reads: 104
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
Nov. 30, 2015 03:15 PM EST Reads: 246
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
Nov. 30, 2015 03:00 PM EST Reads: 494
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
Nov. 30, 2015 02:00 PM EST Reads: 371
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, rich desktop and tuned mobile experiences can now be created with a single codebase – without compromising functionality, performance or usability. In his session at DevOps Su...
Nov. 30, 2015 01:45 PM EST Reads: 435
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningf...
Nov. 30, 2015 01:45 PM EST Reads: 438
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Nov. 30, 2015 01:00 PM EST Reads: 541
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
Nov. 30, 2015 12:45 PM EST Reads: 344
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Nov. 30, 2015 12:45 PM EST Reads: 293